Previous studies evaluating the association between DOACs and cancer either have combined thrombin inhibitors with factor Xa inhibitors [39] or have assessed only cancer mortality in patients who were already diagnosed with cancer or had a relatively short follow-up [40]. This evidence concerns the gene F10 and cancer.